<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>7381697</pmcid><all-ids><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="pmid">32707534</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="pmc">7381697</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="publisher-id">S2213-1582(20)30178-9</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="doi">10.1016/j.nicl.2020.102341</article-id><article-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" pub-id-type="publisher-id">102341</article-id></all-ids><extracted-table><table-id>t0005</table-id><table-label>Table 1</table-label><table-caption>Participants. Controls and TLE characteristics (2nd and 3rd columns) and the three cognitive phenotype groups (4th through 6th columns). Generalized Cognitive Impairment (Generalized-CI), Focal Cognitive Impairment (Focal-CI) and No Cognitive Impairment (No-CI) – refer to TLE patient subgroups identified through the clustering analysis in Section 2.3.1. †Based on adjusted hippocampal z-score of &lt;−1.5. If based on z &lt; −1.0, 43% of TLE exhibited hippocampal atrophy. ‡One value missing from Generalized-CI. Please see text for interpretation of significant differences. (last column).</table-caption><original-table><table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" position="float" id="t0005"><label>Table 1</label><caption><p>Participants. Controls and TLE characteristics (2nd and 3rd columns) and the three cognitive phenotype groups (4th through 6th columns). Generalized Cognitive Impairment (Generalized-CI), Focal Cognitive Impairment (Focal-CI) and No Cognitive Impairment (No-CI) – refer to TLE patient subgroups identified through the clustering analysis in <xref rid="s0040" ref-type="sec">Section 2.3.1</xref>. †Based on adjusted hippocampal z-score of &lt;−1.5. If based on z &lt; −1.0, 43% of TLE exhibited hippocampal atrophy. ‡One value missing from Generalized-CI. Please see text for interpretation of significant differences. (last column).</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Groups</th><th>Controls</th><th>All TLE</th><th>Generalized-CI</th><th>Focal-CI</th><th>No-CI</th><th>p (ANOVA/χ<sup>2</sup>)</th></tr></thead><tbody><tr><td>N</td><td>83</td><td>111</td><td>20</td><td>34</td><td>57</td><td>–</td></tr><tr><td>Age (years) [Mean ± SD]</td><td>33.8 ± 10.6</td><td>39.6 ± 11.5</td><td>38.2 ± 13.5</td><td>36.6 ± 11.1</td><td>41.9 ± 10.4</td><td>0.17</td></tr><tr><td>Gender (Male/Female)</td><td>36/47</td><td>43/68</td><td>8/12</td><td>15/19</td><td>20/37</td><td>0.91</td></tr><tr><td>Education (years) [Mean ± SD]</td><td>15.8 ± 2.7</td><td>14.7 ± 2.7</td><td>12.3 ± 2.0</td><td>13.6 ± 1.7</td><td>16.2 ± 2.4</td><td>&lt;0.001</td></tr><tr><td>Mother Education (year) [Mean ± SD]</td><td>14.6 ± 2.7</td><td>13.5 ± 2.7</td><td>12.6 ± 2.7</td><td>13.8 ± 2.3</td><td>13.6 ± 2.9</td><td>&lt;0.05</td></tr><tr><td>Father Education (years) [Mean ± SD]</td><td>14.8 ± 2.8</td><td>13.8 ± 2.9</td><td>11.9 ± 2.1</td><td>13.2 ± 2.0</td><td>14.7 ± 3.1</td><td>&lt;0.001</td></tr><tr><td>Race (Caucasian/Non-Caucasian)</td><td>74/9</td><td>91/20</td><td>10/10</td><td>26/8</td><td>55/2</td><td>&lt;0.05</td></tr><tr><td>Duration of Seizures (years) [Mean ± SD]</td><td>–</td><td>16.8 ± 13.9</td><td>21.3 ± 16.7</td><td>13.2 ± 12.9</td><td>17.4 ± 13.2</td><td>0.17</td></tr><tr><td>Recurring Seizure Onset Age (years) [Mean ± SD]</td><td>–</td><td>22.8 ± 13.6</td><td>16.8 ± 11.9</td><td>23.4 ± 11.5</td><td>24.5 ± 14.6</td><td>0.17</td></tr><tr><td>Drug Onset Age (years) [Mean ± SD]</td><td>–</td><td>25.7 ± 13.6</td><td>18.3 ± 11.1</td><td>24.4 ± 11.2</td><td>29.0 ± 14.5</td><td>&lt;0.05</td></tr><tr><td>Number of Anti-epileptic Drugs [Mean ± SD]</td><td>–</td><td>1.8 ± 0.9</td><td>2.4 ± 0.7</td><td>1.8 ± 1.0</td><td>1.7 ± 0.9</td><td>0.07</td></tr><tr><td>Seizure Laterality (Left/Right/Bilateral/Uncertain)</td><td>–</td><td>57/25/9/20</td><td>9/6/2/3</td><td>17/9/2/6</td><td>31/10/5/11</td><td>0.91</td></tr><tr><td>Seizure Controlled for &gt;1 year (Yes/No)</td><td>–</td><td>61/50</td><td>8/12</td><td>20/14</td><td>33/24</td><td>0.66</td></tr><tr><td>Hippocampal Atrophy (HA) [unilateral/bilateral]<sup>†</sup></td><td>2.5%</td><td>23%</td><td>33% [7%/26%]</td><td>23% [13%/10%]</td><td>20% [11%/10%]</td><td>&lt;0.05</td></tr><tr><td>Generalized Seizure History (Yes/No)</td><td>–</td><td>55/56</td><td>16/4</td><td>15/19</td><td>24/33</td><td>&lt;0.05</td></tr><tr><td>Number of Lifetime Generalized Seizures (0–5/6–50/51+)<sup>‡</sup></td><td>–</td><td>61/40/9</td><td>3/11/5</td><td>19/12/3</td><td>39/17/1</td><td>&lt;0.001</td></tr></tbody></table></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Participants. Controls and TLE characteristics (2nd and 3rd columns) and the three cognitive phenotype groups (4th through 6th columns). Generalized Cognitive Impairment (Generalized-CI), Focal Cognitive Impairment (Focal-CI) and No Cognitive Impairment (No-CI) – refer to TLE patient subgroups identified through the clustering analysis in ???. †Based on adjusted hippocampal z-score of &lt;−1.5. If based on z &lt; −1.0, 43% of TLE exhibited hippocampal atrophy. ‡One value missing from Generalized-CI. Please see text for interpretation of significant differences. (last column).</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th>Groups</th><th>Controls</th><th>All TLE</th><th>Generalized-CI</th><th>Focal-CI</th><th>No-CI</th><th>p (ANOVA/χ2)</th></tr></thead><tbody><tr><td>N</td><td>83</td><td>111</td><td>20</td><td>34</td><td>57</td><td>–</td></tr><tr><td>Age (years) [Mean ± SD]</td><td>33.8 ± 10.6</td><td>39.6 ± 11.5</td><td>38.2 ± 13.5</td><td>36.6 ± 11.1</td><td>41.9 ± 10.4</td><td>0.17</td></tr><tr><td>Gender (Male/Female)</td><td>36/47</td><td>43/68</td><td>8/12</td><td>15/19</td><td>20/37</td><td>0.91</td></tr><tr><td>Education (years) [Mean ± SD]</td><td>15.8 ± 2.7</td><td>14.7 ± 2.7</td><td>12.3 ± 2.0</td><td>13.6 ± 1.7</td><td>16.2 ± 2.4</td><td>&lt;0.001</td></tr><tr><td>Mother Education (year) [Mean ± SD]</td><td>14.6 ± 2.7</td><td>13.5 ± 2.7</td><td>12.6 ± 2.7</td><td>13.8 ± 2.3</td><td>13.6 ± 2.9</td><td>&lt;0.05</td></tr><tr><td>Father Education (years) [Mean ± SD]</td><td>14.8 ± 2.8</td><td>13.8 ± 2.9</td><td>11.9 ± 2.1</td><td>13.2 ± 2.0</td><td>14.7 ± 3.1</td><td>&lt;0.001</td></tr><tr><td>Race (Caucasian/Non-Caucasian)</td><td>74/9</td><td>91/20</td><td>10/10</td><td>26/8</td><td>55/2</td><td>&lt;0.05</td></tr><tr><td>Duration of Seizures (years) [Mean ± SD]</td><td>–</td><td>16.8 ± 13.9</td><td>21.3 ± 16.7</td><td>13.2 ± 12.9</td><td>17.4 ± 13.2</td><td>0.17</td></tr><tr><td>Recurring Seizure Onset Age (years) [Mean ± SD]</td><td>–</td><td>22.8 ± 13.6</td><td>16.8 ± 11.9</td><td>23.4 ± 11.5</td><td>24.5 ± 14.6</td><td>0.17</td></tr><tr><td>Drug Onset Age (years) [Mean ± SD]</td><td>–</td><td>25.7 ± 13.6</td><td>18.3 ± 11.1</td><td>24.4 ± 11.2</td><td>29.0 ± 14.5</td><td>&lt;0.05</td></tr><tr><td>Number of Anti-epileptic Drugs [Mean ± SD]</td><td>–</td><td>1.8 ± 0.9</td><td>2.4 ± 0.7</td><td>1.8 ± 1.0</td><td>1.7 ± 0.9</td><td>0.07</td></tr><tr><td>Seizure Laterality (Left/Right/Bilateral/Uncertain)</td><td>–</td><td>57/25/9/20</td><td>9/6/2/3</td><td>17/9/2/6</td><td>31/10/5/11</td><td>0.91</td></tr><tr><td>Seizure Controlled for &gt;1 year (Yes/No)</td><td>–</td><td>61/50</td><td>8/12</td><td>20/14</td><td>33/24</td><td>0.66</td></tr><tr><td>Hippocampal Atrophy (HA) [unilateral/bilateral]†</td><td>2.5%</td><td>23%</td><td>33% [7%/26%]</td><td>23% [13%/10%]</td><td>20% [11%/10%]</td><td>&lt;0.05</td></tr><tr><td>Generalized Seizure History (Yes/No)</td><td>–</td><td>55/56</td><td>16/4</td><td>15/19</td><td>24/33</td><td>&lt;0.05</td></tr><tr><td>Number of Lifetime Generalized Seizures (0–5/6–50/51+)‡</td><td>–</td><td>61/40/9</td><td>3/11/5</td><td>19/12/3</td><td>39/17/1</td><td>&lt;0.001</td></tr></tbody></table></div></transformed-table></extracted-table></extracted-tables-set>